BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 11013277)

  • 1. Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines.
    Berruti A; Sperone P; Bottini A; Gorzegno G; Lorusso V; Brunelli A; Botta M; Tampellini M; Donadio M; Mancarella S; De Lena M; Alquati P; Dogliotti L
    J Clin Oncol; 2000 Oct; 18(19):3370-7. PubMed ID: 11013277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines.
    Pieńkowski T; Jagiello-Gruszfeld A
    Int J Clin Pharmacol Res; 2001; 21(3-4):111-7. PubMed ID: 12067140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study.
    Gasparini G; Caffo O; Barni S; Frontini L; Testolin A; Guglielmi RB; Ambrosini G
    J Clin Oncol; 1994 Oct; 12(10):2094-101. PubMed ID: 7931479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vinorelbine and infusional 5-fluorouracil in anthracycline and taxane pre-treated metastatic breast cancer.
    Stuart NS; McIllmurray MB; Bishop JL; Johnston SR; Price CG; O'Reilly SM; Joffe JK; Neave F; Whipp EC
    Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):152-6. PubMed ID: 18083354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: a phase II study.
    Nolè F; Munzone E; Mandalà M; Catania C; Orlando L; Zampino MG; Minchella I; Colleoni M; Peruzzotti G; Marrocco E; Goldhirsch A
    Ann Oncol; 2001 Jan; 12(1):95-100. PubMed ID: 11249057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
    Fan Y; Xu B; Yuan P; Wang J; Ma F; Li Q; Zhang P; Li Q; Cai R
    Chemotherapy; 2010; 56(4):340-7. PubMed ID: 20720418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity and safety of vinorelbine combined with doxorubicin or fluorouracil as first-line therapy in advanced breast cancer: a stratified phase II study.
    Hochster HS; Vogel CL; Burman SL; White R
    Oncologist; 2001; 6(3):269-77. PubMed ID: 11423674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: a phase II study.
    Donadio M; Ardine M; Berruti A; Ritorto G; Fea E; Mistrangelo M; Coccorullo Z; Bergnolo P; Comandone A; Bertetto O
    Cancer Chemother Pharmacol; 2003 Aug; 52(2):147-52. PubMed ID: 12764672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vinorelbine and 5-fluorouracil bolus and/or continuous venous infusion plus levofolinic acid as second-line chemotherapy for metastatic breast cancer: an analysis of results in clinical practice of the Gruppo Oncologico Italia Meridionale (GOIM).
    Gebbia V; Caruso M; Borsellino N; Ajello R; Tirrito ML; Chiarenza M; Valenza R; Verderame F; Varvara F; Marrazzo A; Bajardi E; Ferrao F; Bordonaro R; Tralongo P
    Anticancer Res; 2006; 26(4B):3143-50. PubMed ID: 16886648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method.
    Dieras V; Extra JM; Bellissant E; Espie M; Morvan F; Pierga JY; Mignot L; Tresca P; Marty M
    J Clin Oncol; 1996 Dec; 14(12):3097-104. PubMed ID: 8955654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer.
    Welt A; von Minckwitz G; Oberhoff C; Borquez D; Schleucher R; Loibl S; Harstrick A; Kaufmann M; Seeber S; Vanhoefer U
    Ann Oncol; 2005 Jan; 16(1):64-9. PubMed ID: 15598940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor.
    Kornek GV; Ulrich-Pur H; Penz M; Haider K; Kwasny W; Depisch D; Kovats E; Lang F; Schneeweiss B; Scheithauer W
    J Clin Oncol; 2001 Feb; 19(3):621-7. PubMed ID: 11157011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer.
    Delozier T; Guastalla JP; Yovine A; Levy C; Chollet P; Mousseau M; Delva R; Coeffic D; Vannetzel JM; Zazzi ES; Brienza S; Cvitkovic E
    Anticancer Drugs; 2006 Oct; 17(9):1067-73. PubMed ID: 17001180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer.
    Tawfik H; Rostom Y; Elghazaly H
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):913-9. PubMed ID: 23344713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of refractory metastatic breast cancer with 5-fluorouracil and levofolinic acid as 48 hours continuous venous infusion.
    Gebbia V; Mauceri G; Testa A; Tirrito M; Varvara F; Cucchiara A; Borsellino N; Girlando A; Ferrara M; Caruso F
    Anticancer Res; 1999; 19(3B):2289-92. PubMed ID: 10472346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vinorelbine and fluorouracil plus leucovorin combination (ViFL) in patients with anthracycline and taxane-pretreated metastatic breast cancer: a phase II study.
    Oliva C; Bergnolo P; Inguì M; Bianco L; Pochettino P; Cutin SC; Boglione A; Dal Canton O; Garetto F; Comandone A
    J Cancer Res Clin Oncol; 2010 Mar; 136(3):411-7. PubMed ID: 19727815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of refractory metastatic breast cancer with 5-fluorouracil plus levofolinic acid as continuous venous infusion: a phase II study.
    Gebbia V; Borsellino N; Testa A; Tirrito M; Varvara F; Cucchiara A; Mauceri G; Girlando A; Ferrara M; Caruso F
    Anticancer Res; 1999; 19(4C):3553-7. PubMed ID: 10629652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: a regimen with a low subjective toxic burden.
    Nolè F; de Braud F; Aapro M; Minchella I; De Pas TM; Zampino MG; Monti S; Andreoni G; Goldhirsch A
    Ann Oncol; 1997 Sep; 8(9):865-70. PubMed ID: 9358936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure.
    Bonneterre J; Roché H; Monnier A; Guastalla JP; Namer M; Fargeot P; Assadourian S
    Br J Cancer; 2002 Nov; 87(11):1210-5. PubMed ID: 12439707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.